A prospective, split-face study comparing 1,064-nm picosecond Nd:YAG laser toning with 1,064-nm Q-switched Nd:YAG laser toning in the treatment of melasma

Hong, Jun Ki; Shin, Sun Hye; Park, Su Jung; Seo, Seong Jun; Park, Kui Young

doi:10.1080/09546634.2022.2033674

Cited by 10 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…Certain studies tried to find the differences in efficacy and adverse events according to pulse duration or pulse delivery [ 13 , 26 , 33 ]. Comparing QSNY and picosecond Nd:YAG laser (PSNY) in terms of the efficacy, there was no significant difference between both modalities [ 13 ]. Dual-pulsed QSNY, which is also known as PTP (photoacoustic twin pulse) mode, was noninferior to single-pulsed QSNY in terms of efficacy with significantly less pain [ 26 ].…”

Section: Resultsmentioning

confidence: 99%

“…However, in clinical practice, PSNY is not markedly superior to LFQSNY in melasma, yet it is still preferred in tattoo removal and acne scar treatment. Although there are only few reports, a split-face study comparing LFPSNY and LFQSNY for treating melasma demonstrated that neither was superior in pigment lightening [ 13 ]. However, the fractionated picosecond laser beam may enhance the efficacy and safety of melasma treatment by rejuvenating the dermal environment.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The Low-Fluence Q-Switched Nd:YAG Laser Treatment for Melasma: A Systematic Review

Lee

et al. 2022

Medicina

View full text Add to dashboard Cite

Melasma is a common pigmentary disorder with a complex pathogenesis, of which the treatment is challenging. Conventional treatment often leads to inconsistent results with unexpected pigmentary side effects and high recurrence rates. Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. We reviewed literatures on the LFQSNY treatment of melasma published between 2009 and May 2022 to evaluate the efficacy and adverse events, including its combination therapy. A systematic PubMed search was conducted and a total of 42 articles were included in this study. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin. Although few studies have reported considerable recurrence rates three months after treatment, unfortunately, there is a lack of the long-term follow-up results of LFQSNY in melasma. To enhance the effectiveness and reduce the adverse events, LFQSNY has been used in combination with other treatment modalities in melasma, including topical bleaching agents, oral tranexamic acid, chemical peeling, or diverse energy-based devices, which generally reduced side effects with or without significant superior efficacy compared to LFQSNY alone.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Low-Fluence Q-Switched Nd:YAG Laser Treatment for Melasma: A Systematic Review

Lee

et al. 2022

Medicina

View full text Add to dashboard Cite

show abstract

“…Anyway, additional studies are needed to provide a more accurate understanding of the underlying mechanisms for the efficacy difference of Picos in treating melasma. Previous studies have shown that PSNYL is effective for melasma in both fractional (11,15) and non-fractional (14,16,17) modes, and we chose to conduct the study in the non-fractional mode, which is a more economical option for patients. This was the first demonstration that the MASI score declined significantly after just one treatment session of PSNYL compared to baseline (p < 0.001).…”

Section: Discussionmentioning

confidence: 99%

Comparison of the efficacy and safety of picosecond Nd:YAG laser (1,064 nm), picosecond alexandrite laser (755 nm) and 2% hydroquinone cream in the treatment of melasma: A randomized, controlled, assessor-blinded trial

et al. 2023

View full text Add to dashboard Cite

BackgroundIncreasing numbers of studies demonstrated that picosecond lasers (Picos) were effective and safe for melasma. However, A limited number of randomized controlled trials (RCTs) regarding Picos contribute to a modest level of evidence. Topical hydroquinone (HQ) remains to be the first-line therapy.ObjectiveTo compare the efficacy and safety of non-fractional picosecond Nd:YAG laser (PSNYL), non-fractional picosecond alexandrite laser (PSAL), and 2% HQ cream in the treatment of melasma.MethodSixty melasma patients with Fitzpatrick skin types (FST) III-IV were randomly assigned to the PSNY, PSAL, and HQ groups at a 1:1:1 ratio. Patients in PSNYL and PSAL groups received 3 laser sessions at 4-week intervals. The 2% HQ cream was applied twice daily for 12 weeks in patients of the HQ group. The primary outcome, the melasma area and severity index (MASI) score, was evaluated at weeks 0, 4, 8, 12, 16, 20, and 24. The patient assessment score by quartile rating scale was rated at weeks 12, 16, 20, and 24.ResultsFifty-nine (98.3%) subjects were included in the analysis. Each group showed significant change from baseline in MASI scores from week 4 to week 24. The MASI score in the PSNYL group showed the greatest reduction compared to the PSAL group (p = 0.016) and HQ group (p = 0.018). The PSAL group demonstrated comparable MASI improvement as the HQ group (p = 0.998). The PSNYL group had the highest patient assessment score, followed by the PSAL group and then the HQ group, although only the differences between PSNYL and HQ groups at weeks 12 and 16 were significant. Four patients (6.8%) experienced recurrence. Other unanticipated events were transient and subsided after 1 week to 6 months.ConclusionThe efficacy of non-fractional PSNYL was superior to that of non-fractional PSAL, which was not inferior to 2% HQ, thus non-fractional Picos providing an alternative for melasma patients with FSTs III-IV. The safety profiles of PSNYL, PSAL, and 2% HQ cream were similar.Clinical Trial Registrationhttps://www.chictr.org.cn/showprojen.aspx?proj=130994, ChiCTR2100050089.

show abstract

“…2,3 However, there are reports that the effect of the picosecond laser is not significantly superior to that of the conventional nanosecond laser to pigmented lesions. 4,5 Recently, picosecond lasers were shown to be effective in not only treating non-pigmented disorders, including acne and scars, but also in aiding skin rejuvenation. Additionally, picosecond lasers induce intraepidermal and dermal vacuole formation through laser-induced optical breakdown (LIOB).…”

Section: Introductionmentioning

confidence: 99%

Review of picosecond lasers in non-pigmented disorders

et al. 2022

Self Cite

View full text Add to dashboard Cite

Based on the principles of the selective photothermolysis theory, picosecond lasers can enhance the therapeutic effect on the target tissue and minimize damage to the surrounding tissue. Therefore, picosecond lasers have significant advantages over conventional laser techniques in terms of effectiveness, safety, and therapeutic effect on the pigmented skin. Additionally, picosecond lasers induce intraepidermal and dermal vacuole formation through laser-induced optical breakdown, which is associated with dermal remodeling by increasing dermal collagen and elastin formation. Based on these additional findings, picosecond lasers are reportedly effective in treating non-pigmented disorders, scars, and in cutaneous rejuvenation. Herein, we review the literature on the treatment of non-pigmented disorders by a picosecond laser and confirm its efficacy.

show abstract

A prospective, split-face study comparing 1,064-nm picosecond Nd:YAG laser toning with 1,064-nm Q-switched Nd:YAG laser toning in the treatment of melasma

Cited by 10 publications

References 25 publications

The Low-Fluence Q-Switched Nd:YAG Laser Treatment for Melasma: A Systematic Review

The Low-Fluence Q-Switched Nd:YAG Laser Treatment for Melasma: A Systematic Review

Comparison of the efficacy and safety of picosecond Nd:YAG laser (1,064 nm), picosecond alexandrite laser (755 nm) and 2% hydroquinone cream in the treatment of melasma: A randomized, controlled, assessor-blinded trial

Review of picosecond lasers in non-pigmented disorders

Contact Info

Product

Resources

About